Nonviral transfer of the gene encoding coagulation factor viii in patients with severe hemophilia A

New England Journal of Medicine

Volumn 344, Issue 23, 2001, Pages 1735-1742

  Roth, David A ^a,d   Tawa Jr , Nicholas E ^b   O'Brien, Joanne M ^a   Treco, Douglas A ^c   Selden, Richard F ^c  

^a Department of Medicine   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Shire Canada   (Canada)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL SECRETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FIBROBLAST; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HEMOPHILIA A; HUMAN; OMENTUM; PLASMID; PRIORITY JOURNAL; SKIN BIOPSY;

ADULT; AGED; BIOPSY; CLONE CELLS; FACTOR VIII; FIBROBLASTS; GENE THERAPY; HEMOPHILIA A; HEMORRHAGE; HUMANS; LAPAROSCOPY; MIDDLE AGED; OMENTUM; PLASMIDS; SKIN; TRANSFECTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0035822005     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200106073442301     Document Type: Article

References (22)

1. Clinical aspects and therapy of hemophilia
2. The diagnosis of hemophilia A and B and von Willebrand's disease
3. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B
4. Results of secondary prophylaxis in children with severe hemophilia
5. A new variant of Creutzfeldt-Jakob disease in the UK
6. Prions and haemophilia: Assessment of risk
7. Review of the hepatitis A epidemics in hemophiliacs in Europe
8. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: Parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses
9. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates
10. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses
11. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate
12. Advances toward gene therapy for hemophilia at the millennium
13. Implantation of genetically engineered fibroblasts into mice: Implications for gene therapy
14. Regulation of insulin-gene expression: Implications for gene therapy
15. Long-term production and delivery of human growth hormone in viva
16. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity
17. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule
18. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
19. Hemophilia: A new approach to an old disease
20. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
21. Evidence for gene transfer and expression of factor IX in haemophilia B patients with an AAV vector